Bristol Myers Squibb Reports meta-analysis Data for Remternetug in Renal cell carcinoma

Bristol Myers Squibb today announced meta-analysis results for Remternetug in patients with Renal cell carcinoma. The study demonstrated that Remternetug improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Renal cell carcinoma and support the continued development of Remternetug in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Remternetug was consistent with previous observations, with no new safety signals identified.